



Supplementary Figure 3. Treatment with PI-3K/Akt inhibitor abrogates β -catenin activation in TNF α treated glioma cells. Cells were treated with TNF α in the presence and absence of 10 μ M of PI-3K/Akt inhibitor LY294002 for 12 hours and Western blot assay was performed to determine levels of active β -catenin.